Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
about
In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporinFive-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study GroupCefdinir: an expanded-spectrum oral cephalosporin.Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study GroupAntimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae.In vitro activity and susceptibility to hydrolysis of S-1006.Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections.Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci.MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses.In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenemComparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens.In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
P2860
Q24676500-D8C5615F-959F-4006-B626-20FAC3D122F0Q33695191-083EF411-7104-407A-8568-68BB455EA7F4Q34122535-34D48B26-9929-4E4C-9965-C4792161FBECQ35134633-036E567A-576E-4989-87D6-6C78309CC833Q35136539-8EF14961-81B3-4651-B44E-C973E11DE401Q35842862-A962C818-71EA-4BB8-902D-5793DE81D7E6Q35862953-085FC486-BBD4-4C72-AC96-5171201569BFQ36723783-77F6AC2F-EDCE-4294-9DA8-DE40CEAB6DE1Q37072463-233D1294-EAB0-4BEB-9CBC-7BDD06D1DA31Q37115080-05F2DA5D-367D-4A04-936F-8471F9A6290DQ37118146-9BE38230-B3EC-4E30-8DEB-B54BE5F6DEA6Q39556898-006BEFCB-155A-475F-AEAC-EEEB041EC98EQ39779693-6FB101ED-C12B-425D-A400-3BBECF475EB0Q39785414-FDC8F136-8EC8-4CAF-BD56-DE5E7775C910Q43986309-97F9D15B-F237-4F01-B262-09650395635DQ53802143-2F5D2EB7-AF21-4EAE-AE00-51130ADC7C87
P2860
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@en
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@nl
type
label
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@en
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@nl
prefLabel
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@en
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@nl
P2093
P2860
P356
P1476
Comparative in vitro activity ...... 482, a new oral cephalosporin.
@en
P2093
P2860
P304
P356
10.1128/AAC.33.10.1795
P407
P577
1989-10-01T00:00:00Z